# A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants

> **NCT02034162** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 295 (actual)

## Conditions studied

- Helminth Infections

## Interventions

- **DRUG:** Mebendazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02034162
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2016-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034162, "A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02034162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*